Catalyst Event
BioNTech SE (BNTX) · Other
From KEDI U.S. Medical AI Index (KUSMAI)
5/30/2026, 12:00:00 AM
Announced encouraging interim Phase 2 data for its lung cancer treatment candidate, pumitamig, in partnership with Bristol Myers Squibb, at the ASCO annual meeting on May 30, 2026.
Korean Translation
2026년 5월 30일, 미국 임상종양학회(ASCO) 연례회의에서 브리스톨 마이어스 스큅과 공동 개발 중인 폐암 치료제 후보물질 '푸미타미그'의 긍정적인 임상 2상 중간 데이터를 발표함.
Related Recent Events
Alphabet Inc (GOOGL) · Earnings Release
Alphabet Q2 2026 earnings release scheduled for July 22, 2026, with analysts forecasting EPS of approximately $2.85-$2.87 forecasted.
7/22/2026, 12:00:00 AM
Alphabet Inc (GOOGL) · Other
Alphabet held its 2026 Annual Meeting of Shareholders on June 5, 2026. Proposals included an increase to the 2021 Stock Plan share reserve.
6/5/2026, 12:00:00 AM
Hims & Hers Health Inc (HIMS) · Other
Hims & Hers appointed Dr. Anant Vinjamoori as its new Chief Medical Officer on 2026-06-04, which resulted in a 7.23% stock price increase.
6/4/2026, 12:00:00 AM
Natera Inc (NTRA) · Other
Announced a strategic collaboration with CytoDyn to use its ctDNA platform to support CytoDyn's metastatic colorectal cancer development program.
6/4/2026, 12:00:00 AM
Eli Lilly and Co (LLY) · Other
Announced on 2026-06-03 plans to halve its €2.3 billion investment in a new German plant; medium impact estimated due to regulatory headwinds and reduced growth capacity, expected.
6/3/2026, 12:00:00 AM
Alphabet Inc (GOOGL) · Other
The UK's Competition & Markets Authority (CMA) announced on June 3, 2026, new conduct requirements for Google's AI-powered search, giving publishers more control over their content.
6/3/2026, 12:00:00 AM